InMed Pharmaceuticals, Inc. engages in the provision of biopharmaceutical research. It operates through the InMed Pharma and BayMedica segments. The InMed Pharma segment is organized around the research and development of small molecule pharmaceuticals drug candidates. The BayMedica segment focuses on the manufacturing technologies to produce and commercialize bulk rare cannabinoids for sale as ingredients in the health and wellness industry. It is also involved in cannabinoid-based therapies and a biosynthesis system for the manufacturing of pharmaceutical-grade cannabinoids. The company was founded by Christopher Bogart, Sazzad Hossain, Hyder A. Khoja, and Craig D. Schneider on May 19, 1981 and is headquartered in Vancouver, Canada.
相关临床试验
10
6 进行中
药物批准
0
批准总数
监管机构
0
监管机构数
成立时间
N/A
进行中（未招募）
5
50.0%
已完成
2
20.0%
尚未招募
1
10.0%
招募中
2
20.0%
暂无批准数据
- Mentari Therapeutics plans to go public through a reverse merger with InMed Pharmaceuticals, creating a combined company valued at $421 million focused on antibody drugs for migraine prevention. - The deal includes a $290 million private placement led by Fairmount and other major investors, providing funding through 2028 to support clinical development of two lead programs targeting the PACAP protein. - Mentari's approach targets PACAP, a nervous system protein that regulates stress and triggers migraine symptoms, offering potential relief for patients inadequately controlled by current CGRP-blocking therapies. - The company's lead programs MT-001 and MT-002 are expected to deliver Phase 2 proof-of-concept data by 2028 and Phase 1 data by 2027, respectively.
- InMed Pharmaceuticals reported positive preclinical data showing INM-901 significantly reduced neuroinflammation in 3D human brain organoid models of Alzheimer's disease. - The compound demonstrated dose-dependent reduction of key pro-inflammatory markers IL-6 and IL-8 in both general neuroinflammation and Alzheimer's-specific organoid models. - Results provide supportive evidence for mechanistic translation from animal models to human tissue systems, de-risking the program ahead of planned Phase 1 clinical trials. - The company plans to conduct a pre-IND meeting with the FDA in Q3 2026 and targets IND submission and Phase 1 trial initiation in 2027.
- InMed Pharmaceuticals announced the wind down of its BayMedica subsidiary's commercial operations due to pending U.S. federal legislation that would prohibit certain cannabinoid business activities. - The company will refocus exclusively on advancing its pharmaceutical pipeline, including INM-901 for Alzheimer's disease and INM-089 for dry age-related macular degeneration toward IND filings. - BayMedica expects to incur approximately $670,000 in wind-down costs, including severance and operational expenses, with completion targeted before June 30, 2026. - The strategic pivot enables InMed to concentrate internal resources on CB1/CB2 receptor-targeting drug candidates with greater long-term shareholder value potential.
- InMed Pharmaceuticals successfully completed pharmacokinetic studies of INM-901 in large animal models, demonstrating robust bioavailability and therapeutic levels of systemic exposure over a seven-day dosing period. - Neurological assessments revealed no adverse neural or behavioral effects, reinforcing the compound's favorable safety profile and supporting advancement toward first-in-human clinical trials. - The company is preparing for a pre-IND meeting with the FDA and advancing chemistry, manufacturing, and controls development to scale the INM-901 manufacturing process. - These results mark the first preclinical study using the oral formulation of INM-901 in large animals and will guide the design of Phase 1 clinical trials for this Alzheimer's disease candidate.
- DelveInsight reports over 50 pharmaceutical companies are actively developing 55+ cannabinoid therapies across various clinical stages, representing significant momentum in the therapeutic cannabis space. - Recent clinical milestones include positive Phase II results for IGC-AD1 in Alzheimer's agitation, FDA orphan drug designation for BRC-002 in complex regional pain syndrome, and successful Phase I completion for OCT461201. - Leading pipeline candidates target diverse conditions including neurodegenerative diseases, chronic pain, epilepsy, and inflammatory disorders, with multiple drugs advancing through Phase II and Phase III trials. - The expanding pipeline reflects growing clinical validation for cannabinoids in treating conditions like Alzheimer's disease, chronic pain, and rare epilepsy syndromes, supported by increasing medical cannabis legalization.
- InMed Pharmaceuticals announced that INM-901 demonstrated statistically significant reduction of pro-inflammatory cytokines including IL-6, IL-1β, IL-2, and KC/Gro in ex vivo neuroinflammation models. - The compound significantly reduced levels of NLRP3 inflammasome marker, which is increasingly implicated in Alzheimer's disease pathogenesis and neurodegeneration. - INM-901 reduced key pro-inflammatory markers independent of amyloid beta or tau pathology, suggesting potential therapeutic applications across multiple dementia-related diseases. - The results support continued development of INM-901 as a distinctive therapeutic candidate for Alzheimer's disease treatment, with IND-enabling studies planned to follow.
- The FDA has granted Orphan Drug Designation to SKG1108, a gene therapy developed by Skyline Therapeutics, for the treatment of retinitis pigmentosa. - SKG1108 utilizes an adeno-associated virus vector to deliver light-activatable proteins directly to the retina via intravitreal injection. - InMed Pharmaceuticals received three US patents, including one for an ocular drug delivery formulation potentially applicable to age-related macular degeneration (AMD). - A study published in Nature assessed the accuracy of vision assessment tools in the Eye Handbook mobile ophthalmology application, finding potential utility as a screening tool.
